Cargando…
12-Month Teriparatide Treatment Reduces New Vertebral Compression Fractures Incidence And Back Pain And Improves Quality Of Life After Percutaneous Kyphoplasty In Osteoporotic Women
PURPOSE: Define the effectiveness of teriparatide (TPTD) treatment on reducing the incidence of new vertebral compression fractures (NVCFs) and back pain and improving quality of life after percutaneous kyphoplasty (PKP). METHODS: Two years of clinical follow-up data from primary osteoporotic women...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6778479/ https://www.ncbi.nlm.nih.gov/pubmed/31631990 http://dx.doi.org/10.2147/CIA.S224663 |
_version_ | 1783456772377280512 |
---|---|
author | Kong, Meng Zhou, Chuanli Zhu, Kai Zhang, Yiran Song, Mengxiong Zhang, Hao Tu, Qihao Ma, Xuexiao |
author_facet | Kong, Meng Zhou, Chuanli Zhu, Kai Zhang, Yiran Song, Mengxiong Zhang, Hao Tu, Qihao Ma, Xuexiao |
author_sort | Kong, Meng |
collection | PubMed |
description | PURPOSE: Define the effectiveness of teriparatide (TPTD) treatment on reducing the incidence of new vertebral compression fractures (NVCFs) and back pain and improving quality of life after percutaneous kyphoplasty (PKP). METHODS: Two years of clinical follow-up data from primary osteoporotic women who had experienced initial osteoporotic vertebral compression fractures (OVCFs) and received PKP plus 12-month TPTD (n=113) or basic treatment (BT) of calcium and vitamin D supplements (n=208) were retrospectively collected. The risk of NVCFs over each 6-month period in the TPTD group was evaluated and compared with the BT group using a logistic regression. Health-related quality of life (HRQoL, EQ-5D questionnaire), back pain [100 mm visual analog scale (VAS)] and bone mineral density (BMD) of the spine were analyzed using linear mixed models for repeated measures (LMMRM). RESULTS: Logistic regression analysis adjusting for baseline characteristics showed that patients in the TPTD group had a lower risk of NVCFs compared with those receiving BT during the final three observation intervals (6–12 months, OR=0.189, 95% CI=0.030–0.681, p=0.046; 12–18 months, OR=0.009, 95% CI=0.0001–0.111, p=0.001; 18–24 months, OR=0.024, 95% CI=0.0009–0.264, p=0.009, respectively). Significant improvements in adjusted EQ-5D and back pain VAS scores were identified in the TPTD group compared with the BT group, and this improvement was sustained for at least 12 months after teriparatide treatment was discontinued (both p<0.001). The BMD of the spine also showed a higher T-value in the TPTD group compared with the BT group (p<0.001). CONCLUSION: In routine clinical practice, for patients with OVCFs who receive the PKP procedure, TPTD treatment may be a preferable subsequent therapy because of its ability to reduce the incidence of NVCFs and sustain a high quality of life and back pain alleviation. |
format | Online Article Text |
id | pubmed-6778479 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Dove |
record_format | MEDLINE/PubMed |
spelling | pubmed-67784792019-10-18 12-Month Teriparatide Treatment Reduces New Vertebral Compression Fractures Incidence And Back Pain And Improves Quality Of Life After Percutaneous Kyphoplasty In Osteoporotic Women Kong, Meng Zhou, Chuanli Zhu, Kai Zhang, Yiran Song, Mengxiong Zhang, Hao Tu, Qihao Ma, Xuexiao Clin Interv Aging Original Research PURPOSE: Define the effectiveness of teriparatide (TPTD) treatment on reducing the incidence of new vertebral compression fractures (NVCFs) and back pain and improving quality of life after percutaneous kyphoplasty (PKP). METHODS: Two years of clinical follow-up data from primary osteoporotic women who had experienced initial osteoporotic vertebral compression fractures (OVCFs) and received PKP plus 12-month TPTD (n=113) or basic treatment (BT) of calcium and vitamin D supplements (n=208) were retrospectively collected. The risk of NVCFs over each 6-month period in the TPTD group was evaluated and compared with the BT group using a logistic regression. Health-related quality of life (HRQoL, EQ-5D questionnaire), back pain [100 mm visual analog scale (VAS)] and bone mineral density (BMD) of the spine were analyzed using linear mixed models for repeated measures (LMMRM). RESULTS: Logistic regression analysis adjusting for baseline characteristics showed that patients in the TPTD group had a lower risk of NVCFs compared with those receiving BT during the final three observation intervals (6–12 months, OR=0.189, 95% CI=0.030–0.681, p=0.046; 12–18 months, OR=0.009, 95% CI=0.0001–0.111, p=0.001; 18–24 months, OR=0.024, 95% CI=0.0009–0.264, p=0.009, respectively). Significant improvements in adjusted EQ-5D and back pain VAS scores were identified in the TPTD group compared with the BT group, and this improvement was sustained for at least 12 months after teriparatide treatment was discontinued (both p<0.001). The BMD of the spine also showed a higher T-value in the TPTD group compared with the BT group (p<0.001). CONCLUSION: In routine clinical practice, for patients with OVCFs who receive the PKP procedure, TPTD treatment may be a preferable subsequent therapy because of its ability to reduce the incidence of NVCFs and sustain a high quality of life and back pain alleviation. Dove 2019-10-01 /pmc/articles/PMC6778479/ /pubmed/31631990 http://dx.doi.org/10.2147/CIA.S224663 Text en © 2019 Kong et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
spellingShingle | Original Research Kong, Meng Zhou, Chuanli Zhu, Kai Zhang, Yiran Song, Mengxiong Zhang, Hao Tu, Qihao Ma, Xuexiao 12-Month Teriparatide Treatment Reduces New Vertebral Compression Fractures Incidence And Back Pain And Improves Quality Of Life After Percutaneous Kyphoplasty In Osteoporotic Women |
title | 12-Month Teriparatide Treatment Reduces New Vertebral Compression Fractures Incidence And Back Pain And Improves Quality Of Life After Percutaneous Kyphoplasty In Osteoporotic Women |
title_full | 12-Month Teriparatide Treatment Reduces New Vertebral Compression Fractures Incidence And Back Pain And Improves Quality Of Life After Percutaneous Kyphoplasty In Osteoporotic Women |
title_fullStr | 12-Month Teriparatide Treatment Reduces New Vertebral Compression Fractures Incidence And Back Pain And Improves Quality Of Life After Percutaneous Kyphoplasty In Osteoporotic Women |
title_full_unstemmed | 12-Month Teriparatide Treatment Reduces New Vertebral Compression Fractures Incidence And Back Pain And Improves Quality Of Life After Percutaneous Kyphoplasty In Osteoporotic Women |
title_short | 12-Month Teriparatide Treatment Reduces New Vertebral Compression Fractures Incidence And Back Pain And Improves Quality Of Life After Percutaneous Kyphoplasty In Osteoporotic Women |
title_sort | 12-month teriparatide treatment reduces new vertebral compression fractures incidence and back pain and improves quality of life after percutaneous kyphoplasty in osteoporotic women |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6778479/ https://www.ncbi.nlm.nih.gov/pubmed/31631990 http://dx.doi.org/10.2147/CIA.S224663 |
work_keys_str_mv | AT kongmeng 12monthteriparatidetreatmentreducesnewvertebralcompressionfracturesincidenceandbackpainandimprovesqualityoflifeafterpercutaneouskyphoplastyinosteoporoticwomen AT zhouchuanli 12monthteriparatidetreatmentreducesnewvertebralcompressionfracturesincidenceandbackpainandimprovesqualityoflifeafterpercutaneouskyphoplastyinosteoporoticwomen AT zhukai 12monthteriparatidetreatmentreducesnewvertebralcompressionfracturesincidenceandbackpainandimprovesqualityoflifeafterpercutaneouskyphoplastyinosteoporoticwomen AT zhangyiran 12monthteriparatidetreatmentreducesnewvertebralcompressionfracturesincidenceandbackpainandimprovesqualityoflifeafterpercutaneouskyphoplastyinosteoporoticwomen AT songmengxiong 12monthteriparatidetreatmentreducesnewvertebralcompressionfracturesincidenceandbackpainandimprovesqualityoflifeafterpercutaneouskyphoplastyinosteoporoticwomen AT zhanghao 12monthteriparatidetreatmentreducesnewvertebralcompressionfracturesincidenceandbackpainandimprovesqualityoflifeafterpercutaneouskyphoplastyinosteoporoticwomen AT tuqihao 12monthteriparatidetreatmentreducesnewvertebralcompressionfracturesincidenceandbackpainandimprovesqualityoflifeafterpercutaneouskyphoplastyinosteoporoticwomen AT maxuexiao 12monthteriparatidetreatmentreducesnewvertebralcompressionfracturesincidenceandbackpainandimprovesqualityoflifeafterpercutaneouskyphoplastyinosteoporoticwomen |